Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 833

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 8
Chunk 833
---
sey served as Chief
Financial Officer of Regado Biosciences, Inc., a biopharmaceutical company. From December 2012 to February 2014, Mr. Elsey served as
Chief Financial Officer of LifeCell Corporation, a privately held regenerative medicine company. Mr. Elsey holds a B.A. in economics
and an M.B.A. in finance from Michigan State University. We believe that Mr. Esley is qualified to serve as a member of our board of
directors because of his extensive professional experience in science and biotechnology companies.

William
“Bill” Enright has been a director and chair of the Compensation Committee of our board since February 2023. He
is a seasoned biotech executive with more than thirty-four years of experience in building and financing both privately held and publicly
held companies and he is currently the Chief Executive Officer and a Director of Barinthus Biotherapurtics plc (NASDAQ: BRNS), which
he helped to take public in April 2021. Prior to Barinthus, Mr. Enright spent more than ten years at Altimmune (NASDAQ: ALT) as a director,
president & chief executive officer, moving multiple programs into clinical testing, completing several acquisitions, and eventually
taking the company public. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. (acquired by Precigen) with increasing
responsibilities, culminating as Head of Business Development. Mr. Enright brings a breadth of experiences in a variety of positions
within the life science/biotech industry, including time as a consultant, a bench scientist and 12 years with Life Technologies, Inc.
(acquired by Thermo-Fisher), working in various senior level licensing, business management, manufacturing and research roles. Mr. Enright
received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins
University. We believe that Mr. Enright is qualified to serve as a member of our board of directors because of his extensive professional
experience in life science/biotech companies and in the management of public companies.

Jason
Hanson has served as a director and chair of the Nominating and Corporate Governance Committee since February 2023. Mr. Hanson
served as Chief Executive Officer and as a director of enGene Inc. from July 2018 to July 2024. He also served as President of enGene
Inc. from